The potential role of PAPP‐A in breast cancer recurrence is further supported, albeit indirectly, by studies of stanniocalcin‐2, which recently was discovered to inhibit the proteolytic activity of PAPP‐A, and hence its ability to liberate IGF‐I 51. This evidence concerns the gene IGF1 and breast cancer.